CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

Abstract Background Mesothelioma is an incurable, apoptosis-resistant cancer caused in most cases by previous exposure to asbestos and is increasing in incidence. It represents a growing health burden but remains under-researched, with limited treatment options. Early promising signals of activity r...

Full description

Bibliographic Details
Main Authors: Dean A. Fennell, Emma Kirkpatrick, Kelly Cozens, Mavis Nye, Jason Lester, Gerard Hanna, Nicola Steele, Peter Szlosarek, Sarah Danson, Joanne Lord, Christian Ottensmeier, Daniel Barnes, Stephanie Hill, Mihalis Kalevras, Tom Maishman, Gareth Griffiths
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Trials
Subjects:
Mesothelioma
PD-L1
Anti-PD-1
Nivolumab
Randomised controlled trial
Quality of life
Online Access:http://link.springer.com/article/10.1186/s13063-018-2602-y

Internet

http://link.springer.com/article/10.1186/s13063-018-2602-y

Similar Items